204 related articles for article (PubMed ID: 20024640)
21. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
[TBL] [Abstract][Full Text] [Related]
22. Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of high-sensitivity C-reactive protein.
Leu HB; Lin CP; Lin WT; Wu TC; Chen JW
Chest; 2004 Oct; 126(4):1032-9. PubMed ID: 15486359
[TBL] [Abstract][Full Text] [Related]
23. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
Ridker PM; Hennekens CH; Buring JE; Rifai N
N Engl J Med; 2000 Mar; 342(12):836-43. PubMed ID: 10733371
[TBL] [Abstract][Full Text] [Related]
24. C-reactive protein and future cardiovascular events in statin-treated patients with angina pectoris: the extended TRUTH study.
Nozue T; Fukui K; Yamamoto S; Kunishima T; Umezawa S; Onishi Y; Tohyama S; Takeyama Y; Morino Y; Yamauchi T; Hibi K; Sozu T; Terashima M; Michishita I;
J Atheroscler Thromb; 2013; 20(9):717-25. PubMed ID: 23748166
[TBL] [Abstract][Full Text] [Related]
25. Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.
Boden WE; Miller MG; McBride R; Harvey C; Snabes MC; Schmidt J; McGovern ME; Fleg JL; Desvigne-Nickens P; Anderson T; Kashyap M; Probstfield JL
Am Heart J; 2020 Jun; 224():65-76. PubMed ID: 32335402
[TBL] [Abstract][Full Text] [Related]
26. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
[TBL] [Abstract][Full Text] [Related]
28. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Sellmayer A; Limmert T; Hoffmann U
Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
[TBL] [Abstract][Full Text] [Related]
29. A Test in Context: High-Sensitivity C-Reactive Protein.
Ridker PM
J Am Coll Cardiol; 2016 Feb; 67(6):712-723. PubMed ID: 26868696
[TBL] [Abstract][Full Text] [Related]
30. The JUPITER trial: How will it change clinical practice?
Watson KE
Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
[TBL] [Abstract][Full Text] [Related]
31. [Inflammation and lipids in the coronary pathology. Risk factors, causes or therapeutic target?].
Filardi PP; Cecere M; Savarese G; Damore C; Parente A; Conte S; Coutsoumbas G
G Ital Cardiol (Rome); 2010 Dec; 11(12 Suppl 3):10S-15S. PubMed ID: 21491734
[TBL] [Abstract][Full Text] [Related]
32. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
[TBL] [Abstract][Full Text] [Related]
33. The effect of including C-reactive protein in cardiovascular risk prediction models for women.
Cook NR; Buring JE; Ridker PM
Ann Intern Med; 2006 Jul; 145(1):21-9. PubMed ID: 16818925
[TBL] [Abstract][Full Text] [Related]
34. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
Ridker PM; Rifai N; Rose L; Buring JE; Cook NR
N Engl J Med; 2002 Nov; 347(20):1557-65. PubMed ID: 12432042
[TBL] [Abstract][Full Text] [Related]
35. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD; Aday AW; Rose LM; Ridker PM
Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
[TBL] [Abstract][Full Text] [Related]
36. [High sensitivity of C-reactive protein in primary prevention].
Corrado E; Novo S
G Ital Cardiol (Rome); 2007 Jun; 8(6):327-34. PubMed ID: 17633905
[TBL] [Abstract][Full Text] [Related]
37. Circulating biomarkers for long-term cardiovascular risk stratification in apparently healthy individuals from the MONICA 10 cohort.
Frary CE; Blicher MK; Olesen TB; Stidsen JV; Greve SV; Vishram-Nielsen JK; Rasmussen SL; Olsen MH; Pareek M
Eur J Prev Cardiol; 2020 Apr; 27(6):570-578. PubMed ID: 31718257
[TBL] [Abstract][Full Text] [Related]
38. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk".
Ridker PM; Macfadyen JG; Nordestgaard BG; Koenig W; Kastelein JJ; Genest J; Glynn RJ
Circ Cardiovasc Qual Outcomes; 2010 Sep; 3(5):447-52. PubMed ID: 20736443
[TBL] [Abstract][Full Text] [Related]
39. C-reactive protein: a new risk assessment tool for cardiovascular disease.
Clearfield MB
J Am Osteopath Assoc; 2005 Sep; 105(9):409-16. PubMed ID: 16239491
[TBL] [Abstract][Full Text] [Related]
40. Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker.
Jialal I; Devaraj S
Am J Clin Pathol; 2001 Dec; 116 Suppl():S108-15. PubMed ID: 11993695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
